<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01705080</url>
  </required_header>
  <id_info>
    <org_study_id>1201</org_study_id>
    <nct_id>NCT01705080</nct_id>
  </id_info>
  <brief_title>IntErnational Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN</brief_title>
  <acronym>EnligHTN-II</acronym>
  <official_title>IntErnational Non-randomized, Single-arm, Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post market clinical investigation is to further evaluate the safety and
      performance of the EnligHTN™ Renal Denervation System in the treatment of patients with
      uncontrolled hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a post market, prospective, multicenter, non-randomized, single arm study of the
      EnligHTN™ Renal Denervation System. Approximately 500 subjects with uncontrolled hypertension
      will undergo renal artery ablation at approximately 40 investigational sites located
      internationally and will be followed up to five (5) years post procedure.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>• Mean reduction in office Systolic Blood Pressure at six (6) months across all subjects post renal denervation and within sub-groups</measure>
    <time_frame>6 months post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of patients who experience a procedural related event</measure>
    <time_frame>30 days post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of renovascular safety as measured by new renal artery stenosis or aneurysm at the site of ablation</measure>
    <time_frame>6 months, 2 years, and 5 years post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function change based on eGFR</measure>
    <time_frame>6 months, 2 years, and 5 years post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ambulatory Blood Pressure parameters at 6 months</measure>
    <time_frame>6 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office Diastolic Blood Pressure at 6 months</measure>
    <time_frame>6 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving office Systolic Blood Pressure &lt; 140 at 6 month visit</measure>
    <time_frame>6 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Office Blood Pressure parameters at 12, 24, 36, 48, 60 months post denervation</measure>
    <time_frame>12, 24, 36, 48, 60 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ambulatory Blood Pressure parameters at 12, 24, 36, 48, 60 months post denervation</measure>
    <time_frame>12, 24, 36, 48, 60 months post procedure</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">354</enrollment>
  <condition>Hypertension</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>A - EnligHTN for Severe Resistant HTN</arm_group_label>
    <description>Office systolic Blood Pressure ≥160 mmHg
Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Patient has an estimated GFR ≥45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - EnligHTN for Resistant HTN</arm_group_label>
    <description>Office systolic Blood Pressure ≥140 mmHg
Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Patient has an estimated GFR ≥45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - EnligHTN for Resistant HTN &amp; CKD</arm_group_label>
    <description>Office systolic Blood Pressure ≥140 mmHg
Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Patient has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EnligHTN</intervention_name>
    <description>Renal artery ablation with EnligHTN system used for all groups</description>
    <arm_group_label>A - EnligHTN for Severe Resistant HTN</arm_group_label>
    <arm_group_label>B - EnligHTN for Resistant HTN</arm_group_label>
    <arm_group_label>C - EnligHTN for Resistant HTN &amp; CKD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with uncontrolled hypertension
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is ≥ 18 years of age at time of consent

          -  Subject must be able and willing to provide written informed consent

          -  Subject must be able and willing to comply with the required follow-up schedule

          -  Subject has office Systolic Blood Pressure ≥ 140 mmHg at confirmatory visit

          -  Subject has a daytime mean Systolic Ambulatory Blood Pressure &gt; 135 mmHg within 90
             days prior to procedure

          -  Subject has established hypertension (diagnosed ≥12 month prior to baseline) and on a
             guideline based drug regimen at a stable and fully tolerated dose consisting of ≥ 3
             anti-hypertensive medications (including 1 diuretic) or subject has a documented drug
             intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB,
             Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3
             anti-hypertensive drugs.

        Exclusion Criteria:

          -  Subject has significant renovascular abnormalities such as renal artery stenosis &gt; 30%

          -  Subject has undergone prior renal angioplasty, renal denervation, indwelling renal
             stents, and/or abdominal aortic stent grafts

          -  Subject has hemodynamically significant valvular heart disease as determined by study
             investigator

          -  Subject has a life expectancy less than 12 months, as determined by the Investigator

          -  Subject is participating in another clinical study which has the potential to impact
             their hypertension management (pharmaceutical/device/homeopathic)

          -  Subject is pregnant, nursing, or of childbearing potential and is not using adequate
             contraceptive methods

          -  Subject has active systemic infection

          -  Subject has renal arteries with diameter(s) &lt; 4 mm in diameter

          -  Subject has an estimated GFR &lt;15 mL/min per 1.73 m2 using the Modification of Diet in
             Renal Disease (MDRD) formula

          -  Subject had a renal transplant or is awaiting a renal transplant

          -  Subject has blood clotting abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melvin Lobo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIHR Barts Cardiovascular Biomedical Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Worthley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Adelaide Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck Universitatsklinik fur Innere Medizin IV, Nephrologie und Hypertensiologie</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besancon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Cardio. Paris-Sud-Institut Jacques Cartier</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St. Etienne</name>
      <address>
        <city>St. Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Civil - Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-und Diabeteszentrum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bad Krozingen Herzzentrum</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jüdisches Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg GmbH</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinischen Einrichtungen der Universitat Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatskliniken des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ingolstadt</name>
      <address>
        <city>Ingolstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni-Klinik Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University of Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Fondazione Monzino</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana Gabriele/Monasterio - Stabilimento Ospedaliero di Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis Locatie Leyenburg</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Public Hospital</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donsostia</name>
      <address>
        <city>San Sebastián</city>
        <state>Basque</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern General</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2012</study_first_submitted>
  <study_first_submitted_qc>October 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2012</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Denervation</keyword>
  <keyword>Renal artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>December 21, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

